TAM Receptor Tyrosine Kinases in Cancer Drug Resistance

Cancer Research
Mikaella Vouri, Sassan Hafizi

Abstract

Receptor tyrosine kinases (RTK) are major regulators of key biological processes, including cell growth, survival, and differentiation, and were established early on as proto-oncogenes, with aberrant expression linked to tumor progression in many cancers. Therefore, RTKs have emerged as major targets for selective therapy with small-molecule inhibitors. However, despite improvements in survival rates, it is now apparent that the targeting of RTKs with selective inhibitors is only transiently effective, as the majority of patients eventually become resistant to therapy. As chemoresistance is the leading cause of cancer spread, progression, and mortality, there is an increasing need for understanding the mechanisms by which cancer cells can evade therapy-induced cell death. The TAM (Tyro3, Axl, Mer) subfamily of RTKs in particular feature in a variety of cancer types that have developed resistance to a broad range of therapeutic agents, including both targeted as well as conventional chemotherapeutics. This article reviews the roles of TAMs as tumor drivers and as mediators of chemoresistance, and the potential effectiveness of targeting them as part of therapeutic strategies to delay or combat resistance. Cancer Res; 77(11); 277...Continue Reading

References

Jun 2, 2006·Cytokine & Growth Factor Reviews·Sassan Hafizi, Björn Dahlbäck
Jun 6, 2006·Nature Immunology·Anouk CarauxClaude Roth
Jul 13, 2006·The Journal of Experimental Medicine·M Nusrat SharifLionel B Ivashkiv
Oct 27, 2006·The FEBS Journal·Sassan Hafizi, Björn Dahlbäck
Jan 16, 2008·The Journal of Experimental Medicine·Mark A WalletRoland Tisch
Oct 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Shoutian ZhuXu Wu
Nov 12, 2010·The Journal of Investigative Dermatology·Emmanouil S PapadakisEdel A O'Toole
Jul 28, 2011·Journal of Cellular Physiology·Nora B CaberoyWei Li
Oct 7, 2011·Cancer Letters·Anna U Newlaczyl, Lu-Gang Yu
Jul 4, 2012·Nature Genetics·Zhenfeng ZhangTrever G Bivona
Jul 24, 2013·Proceedings of the National Academy of Sciences of the United States of America·Lidia BosurgiCarla V Rothlin
Jul 24, 2013·BioMed Research International·Michelle BuehlerViola Heinzelmann-Schwarz
Nov 5, 2013·Cold Spring Harbor Perspectives in Biology·Greg Lemke
Aug 20, 2014·Cancer Research·Toni M BrandDeric L Wheeler
Jan 9, 2015·Nature Reviews. Cancer·Douglas K GrahamH Shelton Earp
Sep 28, 2016·Molecular Cancer Research : MCR·Kavitha BalajiKhandan Keyomarsi
Nov 20, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Isabel Ben-BatallaSonja Loges

❮ Previous
Next ❯

Citations

Oct 27, 2017·Cell Death & Disease·Katharina StauferWolfgang Mikulits
Apr 14, 2019·Cardiovascular Research·Lucy McShanePasquale Maffia
Oct 31, 2019·Cancer Immunology, Immunotherapy : CII·Marlies J W PeetersPer Thor Straten
Jan 14, 2020·Anti-cancer Drugs·Marco StellatoDaniele Santini
Feb 20, 2020·Journal of Biomolecular Structure & Dynamics·Gatta K R S Naresh, Lalitha Guruprasad
Jun 7, 2019·Archives of Pharmacal Research·Miso Park, Keon Wook Kang
Sep 23, 2020·Advanced Healthcare Materials·Jason V GregoryJoerg Lahann
Aug 5, 2017·BMB Reports·Kyoung Wan Yoon
Mar 21, 2019·Biopolymers·Konstantin AndreevDavid Gidalevitz
Dec 21, 2018·International Journal of Molecular Sciences·Elisa HolsteinWolfgang Mikulits
Oct 24, 2019·Cell Death & Disease·Vinay SagarSarki A Abdulkadir
Dec 1, 2017·Emerging Topics in Life Sciences·Garth W TormoenMichael J Gough
Jul 2, 2020·OncoTargets and Therapy·Lirui HeGuoqing Lv
Feb 5, 2019·Experimental Biology and Medicine·Pei-Ling HsuShaw-Jenq Tsai
May 1, 2020·NPJ Precision Oncology·Ayman M IbrahimHeather L Machado
Jul 29, 2020·Virologica Sinica·Zhao-Yang WangJing An
Apr 20, 2019·International Journal of Molecular Sciences·Teresa Alonso-GordoaJavier Molina-Cerrillo
Sep 26, 2020·Journal of Enzyme Inhibition and Medicinal Chemistry·Shin Hyuck ChungKyung Hoon Min
Jul 4, 2019·Cancer Immunology Research·Marlies J W PeetersPer Thor Straten
Oct 7, 2018·Molecular Cancer Research : MCR·Haley D AxelrodKenneth J Pienta
Jan 23, 2021·RSC Medicinal Chemistry·Daniel J Baillache, Asier Unciti-Broceta
Feb 12, 2021·Biochemical Pharmacology·Monira HoqueLenka Munoz
Feb 18, 2021·NPJ Precision Oncology·Ayman M IbrahimHeather L Machado
Aug 26, 2021·Communications Biology·Tatyana NovoyatlevaRalph T Schermuly
Aug 12, 2021·Molecular Cancer Therapeutics·Sudeep BanerjeeJason K Sicklick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Related Papers

Molecular Cancer Therapeutics
Anupam VermaSunil Sharma
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
Nancy K Gillis, Howard L McLeod
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Quan-ming ZhaoRui Guo
© 2022 Meta ULC. All rights reserved